Product information and disease descriptionProduct descriptionProduct information
Product comparison
12 evidence topics · 11 sources
Effect sizes of DT120 placed beside approved GAD treatments: company presentation
Effect sizes of approved GAD drug classes: meta-analysis of 21 placebo-controlled trials cited by the company
“We conducted an effect size (ES) analysis of 21 double-blind placebo-controlled trials of medications treating DSM-III-R, DSM-IV or ICD-10 GAD using HAM-A change in score from baseline or endpoint score as the main efficacy measure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“comparing all drugs versus placebo, the ES was 0.39. Mean ESs, excluding children, were PGB: 0.50, AH: 0.45, SNRI: 0.42, BZ: 0.38, SSRI: 0.36, AZA: 0.17 and CAM: -0.31.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HAM-A differences from placebo for approved and off-label GAD drugs: network meta-analysis of 89 trials
“This analysis is based on 89 trials, which included 25 441 patients randomly assigned to 22 different active drugs or placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Duloxetine (MD -3·13, 95% credible interval [CrI] -4·13 to -2·13), pregabalin (MD -2·79, 95% CrI -3·69 to -1·91), venlafaxine (MD -2·69, 95% CrI -3·50 to -1·89), and escitalopram (MD -2·45, 95% CrI -3·27 to -1·63) were more efficacious than placebo with relatively good acceptability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Quetiapine (MD -3·60 95% CrI -4·83 to -2·39) had the largest effect on HAM-A but it was poorly tolerated (odds ratio 1·44, 95% CrI 1·16-1·80) when compared with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
DT120 HAM-A differences from placebo in the phase 3 trials
FDA-approved pharmacotherapies for GAD in adults
“Escitalopram has been approved by the FDA for the treatment of GAD in adults” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As an FDA-approved treatment for GAD in adults, immediate release paroxetine has been studied extensively and multiple studies support its efficacy in adults with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adults with GAD, venlafaxine (75–225 mg/day) effectively reduces anxiety symptoms [36–38] and was the first FDA-approved antidepressant for the treatment of GAD in this age group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Duloxetine, a selective 5-HT and norepinephrine reuptake inhibitor, is FDA-approved for the treatment of GAD, MDD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Buspirone, a non-benzodiazepine anxiolytic and 5-HT1A receptor agonist, is approved for the treatment of GAD in adults” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As such, alprazolam is the only benzodiazepine to be formally approved by the FDA for the treatment of GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Most recent FDA approval of a new drug for GAD: differing company statements
Dosing paradigm: single administered dose compared with daily oral therapy
Monitored-administration model: esketamine nasal spray under the SPRAVATO REMS
Monitored-administration model: DT120 session length in the phase 3 trials
Prescriber intent to administer DT120 compared with esketamine: company market research
| Response of high-priority GAD prescribers | DT120 ODT | Esketamine |
|---|---|---|
| Prescribe and administer the treatment in own practice | “51%” | “26%” |
| Refer out (for DT120, the treatment; for esketamine, for esketamine) | “40%” | “61%” |
| Only discuss if a patient raises it (DT120), or refer out for evaluation without specifying esketamine | “9%” | “14%” |
LSD compared with psilocybin: effect duration in healthy participants
| Effect | 15 mg psilocybin | 30 mg psilocybin | 100 µg LSD | 200 µg LSD |
|---|---|---|---|---|
| Effect duration (h), mean ± SD | “5.6 ± 2.2”View highlighted excerpt for this quote | “6.5 ± 2.4”View highlighted excerpt for this quote | “9.3 ± 3.2”View highlighted excerpt for this quote | “11 ± 3.7”View highlighted excerpt for this quote |
“The doses of 100 and 200 µg LSD and 30 mg psilocybin produced comparable subjective effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LSD at both doses had clearly longer effect durations than psilocybin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The elimination half-life values of LSD and psilocin were an average of ~4 h and 2.5 h, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other psychedelic and serotonergic agents in development for GAD and depressive disorders, as listed by the company
Head-to-head clinical comparison of DT120 with an approved GAD treatment
No evidence found.